4.1 Article

Immune Aspects of Sepsis and Hope for New Therapeutics

Journal

CURRENT INFECTIOUS DISEASE REPORTS
Volume 14, Issue 5, Pages 474-483

Publisher

SPRINGER
DOI: 10.1007/s11908-012-0276-2

Keywords

Lipopolysaccharide; Sepsis; Septic shock; Toll-like receptors; Co-stimulatory immune signals; Co-inhibitory immune signals; Sepsis interventions; Hemoperfusion; Apheresis

Funding

  1. Astra-Zenaca
  2. Agennix
  3. Asahi Kasel
  4. David Horn LLC
  5. Baxter
  6. Sirtris

Ask authors/readers for more resources

Marked alterations of the innate and adaptive immune response follow invasive infection and generalized inflammatory states. If left unchecked, this state of immune dysregulation contributes to a myriad of maladaptive cellular responses that culminate in multiple organ dysfunction, septic shock, and lethality. The molecular details of the cell-signaling networks that underlie the pathophysiology of systemic inflammation and sepsis are now increasingly well understood. While a vigorous and effective immune response to invasive pathogens is essential for microbial clearance and host survival, nonresolving, generalized inflammation can induce diffuse endovascular damage, increased capillary permeability, coagulopathy, and widespread tissue damage. Current evidence indicates that a state of relative immune suppression often accompanies sepsis and might provide novel therapeutic options in some patients. An expanding number of potential therapeutic options are now in clinical development to reestablish control and promote resolution over sepsis-induced systemic inflammation and organ dysfunction.

Authors

I am an author on this paper
Click your name to claim this paper and add it to your profile.

Reviews

Primary Rating

4.1
Not enough ratings

Secondary Ratings

Novelty
-
Significance
-
Scientific rigor
-
Rate this paper

Recommended

No Data Available
No Data Available